European Hematology Association Congress | Conference

Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL

June 14th 2025

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.

Real-World Data Confirm Efficacy of Axi-Cel Across Patient-Related Factors in R/R LBCL

June 13th 2025

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL

June 13th 2025

Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.

Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase

June 13th 2025

ASC4START data support potential for asciminib to be standard of care for newly diagnosed chronic myeloid leukemia in chronic phase.

ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia

June 13th 2025

ESAs or danazol in combination with ruxolitinib displayed similar spleen and symptom outcomes in myelofibrosis with anemia.

Olutasidenib Maintenance Generates Durable RFS in IDH1-Mutated AML Following Induction CR/CRi

June 13th 2025

Olutasidenib maintenance led to 83% 4-month RFS rate and 89% 12-month OS rate in IDH1-mutated AML.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL

June 13th 2025

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Ponatinib Is Associated With Improved Survival in Ph+ ALL With MRD Positivity After Induction

June 13th 2025

A post hoc analysis of the PhALLCON study showed response and survival benefits with imatinib in Ph-positive ALL with MRD negativity after induction.

Iptacopan Shows Efficacy Improvements Over Anti-C5 Therapy in Previously Treated Paroxysmal Nocturnal Hemoglobinuria

June 13th 2025

Oral iptacopan monotherapy led to hemoglobin level and transfusion independence benefits vs anti-C5 therapies in paroxysmal nocturnal hemoglobinuria.

Cyclosporin Plus Cyclophosphamide Outperforms SOC Therapy in GVHD Prevention

June 13th 2025

Cyclosporin/cyclophosphamide after allogeneic stem cell transplant improved outcomes vs cyclosporin/methotrexate in high-risk hematologic malignancies.

Dr Fathi on the Efficacy and Safety of Ziftomenib in R/R NPM1-Mutant AML

June 13th 2025

Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.

Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS

June 13th 2025

Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.

Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma

June 13th 2025

Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.

Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo

June 12th 2025

Venetoclax and decitabine-cedazuridine demonstrated complete responses and encouraging survival outcomes in newly diagnosed AML.

Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NPM1/KMT2A-Altered AML

June 12th 2025

Revumenib plus azacitidine and venetoclax yielded high CR rates among older patients with NPM1-mutant/KMT2A-rearranged newly diagnosed AML.

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

June 12th 2025

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress

June 6th 2025

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL

July 3rd 2024

Orelabrutinib plus FCG led to undetectable MRD in all patients with untreated chronic lymphocytic leukemia who completed 12 cycles of therapy

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

June 27th 2024

Liso-cel continued to show improved disease control and EFS and PFS vs SOC in the second-line treatment of patients with large B-cell lymphoma.

TP53 Mutations Are Associated With Unfavorable Prognosis in CLL

June 18th 2024

TP53 mutations have an adverse prognostic role in CLL, regardless of 17p deletion status, in the context of chemoimmunotherapy and targeted agents.

x